The future of therapeutic myocardial angiogenesis.
Despite improvements in its medical and surgical management, ischemic coronary disease remains responsible for significant morbidity, mortality, and economic burden in developed nations. Therapeutic myocardial angiogenesis is an attractive treatment option for patients with end-stage coronary disease who have failed percutaneous and surgical methods of revascularization. Over the past decade, our understanding of the biology of new blood vessel formation has improved significantly, and consequently, the use of growth factors to induce myocardial angiogenesis has been attempted in preclinical and clinical trials. Although growth factor therapy had demonstrated tremendous success in animal models, clinical trials have shown limited benefit in patients with coronary disease. Vascular endothelial growth factors and fibroblast growth factors are perhaps the most potent inducers of angiogenesis that have been used in animal models, and the only ones that have been used in clinical trials. This review outlines the biology of new vessel formation and the effects of these growth factors in the context of myocardial angiogenesis with an emphasis on the effects on the endothelium. It also provides a brief overview of delivery strategies and summarizes the preclinical and clinical evidence relating to exogenous growth factor delivery for myocardial angiogenesis. Lastly, we discuss the limitations and future challenges of angiogenic therapy.
Boodhwani
Munir
M
Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard University Medical School, Boston, MA 02215, USA.
Sodha
Neel R
NR
Laham
Roger J
RJ
Sellke
Frank W
FW
D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D000818:Animals; D003331:Coronary Vessels / Q000187:drug effects / Q000254:growth & development*; D005544:Forecasting; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans; D009206:Myocardium / Q000378:metabolism*; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*
D043925:Angiogenesis Inducing Agents